Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer

References

• Hashim D, Boffetta P, La Vecchia C, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27:926–933.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
   PubMed Web of Science ®Google Scholar
• Gupta M, McCauley J, Farkas A, et al. Clinical practice guidelines on prostate cancer: a critical appraisal. J Urol. 2015;193:1153–1158.
   PubMed Web of Science ®Google Scholar
• Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest. 2011;34:232–243.
   PubMed Web of Science ®Google Scholar
• Cronauer MV, Schulz WA, Burchardt T, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling. Int J Oncol. 2003;23:1095–1102.
   PubMed Web of Science ®Google Scholar
• Miller K, Anderson J, Abrahamsson PA. Treatment of prostate cancer with hormonal therapy in Europe. BJU Int. 2009;103:2–6.
   PubMed Web of Science ®Google Scholar
• Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012;110(Suppl 1):23–29.
   PubMedGoogle Scholar
• Palmberg C, Koivisto P, Visakorpi T, et al. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol. 1999;36:191–196.
   PubMed Web of Science ®Google Scholar
• Kawakami J, Morales A. Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can Urol Assoc J. 2013;7:226–230.
   Web of Science ®Google Scholar
• Santoleri F, Paola Sorice P, Lasala R. Leuprorelin and triptorelin in the treatment of prostate cancer: medication adherence, persistence and economic evaluation in five years of analysis. Int J Pharm Sci Res. 2014;1:101.
   Google Scholar
• Merseburger AS, Hupe MC. An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv Ther. 2016;33:1072–1093.
   PubMed Web of Science ®Google Scholar
• Wex J, Sidhu M, Odeyemi I, et al. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. Clinicoecon Outcomes Res. 2013;5:257–269.
   PubMedGoogle Scholar
• Wilt T, Nair B, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2001;4:CD003506.
   Google Scholar
• Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22:2927–2941.
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596–1605.
   PubMed Web of Science ®Google Scholar
• Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;4:CD006019.
   Google Scholar
• Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol. 2005;23:800–807.
   PubMed Web of Science ®Google Scholar
• Praller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11:14–23.
   PubMedGoogle Scholar
• Fowler JE Jr, Bigler SA, White PC, et al. Hormone therapy for locally advanced prostate cancer. J Urol. 2002;168:546–549.
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–6415.
   PubMed Web of Science ®Google Scholar
• Cannata DH, Kirschenbaum A, Levine AC. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab. 2012;97:360–365.
   PubMed Web of Science ®Google Scholar
• Klotz L. Pharmacokinetic and pharmacodynamics profile of degarelix for prostate cancer. Expert Opin Drug Metab Toxicol. 2015;11:1795–1802.
   PubMed Web of Science ®Google Scholar
• Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173:1036–1038.
   PubMed Web of Science ®Google Scholar
• Wilson AC1, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16:1851–1863.
   PubMed Web of Science ®Google Scholar
• Tsushima T, Nasu Y, Saika T, et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int. 2001;66:135–139.
   PubMed Web of Science ®Google Scholar
• Collette L, Studer UE, Schröder FH, et al. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate. 2001;48:29–39.
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Trialists‘ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–1498.
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Usami M, et al. Study group for the combined androgen blockade therapy of prostate cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437–3445.
   PubMed Web of Science ®Google Scholar
• Eckstein N, Haas B. Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. Eur J Clin Pharmacol. 2014;70:791–798.
   PubMed Web of Science ®Google Scholar
• Persad R. Leuprorelin acetate in prostate cancer: a European update. Int J Clin Pract. 2002;56:389–396.
   PubMed Web of Science ®Google Scholar
• Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989;321:413–418.
   PubMed Web of Science ®Google Scholar
• Schally AV1, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001;22:248–291.
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566–577.
   PubMed Web of Science ®Google Scholar
• Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. PNAS USA. 1982;79:1658–1662.
   PubMed Web of Science ®Google Scholar
• Spitz A, Gittelman M, Karsh LI, et al. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two phase III studies. Res Rep Urol. 2016;8:159–164.
   PubMed Web of Science ®Google Scholar
• Shore ND, Chu F, Moul J, et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2016 Mar 17. DOI:10.1111/bju.13482
   PubMedGoogle Scholar
• Berges R. Eligard: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl. 2005;4:20–25.
   Web of Science ®Google Scholar
• Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci. 2006;27:143–149.
   PubMed Web of Science ®Google Scholar
• Tunn UW, Gruca D, Bacher P. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation. Clin Interv Aging. 2013;8:457–464.
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Björk T, Whitehouse J, et al. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. J Comp Eff Res. 2015;4:447–453.
   PubMed Web of Science ®Google Scholar
• Lee M, Browneller R, Wu Z, et al. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev. 1997;28:121–138.
   PubMed Web of Science ®Google Scholar
• Pandya Y, Sisodiya D, Dashora K. ATRIGEL implants and controlled released drug delivery system. Int J Biopharmaceutics. 2014;5:208–213.
   Google Scholar
• Alphandéry E, Grand-Dewyse P, Lefèvre R, et al. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015;15:1233–1255.
   PubMed Web of Science ®Google Scholar
• Schulman C, Alcaraz A, Berges R, et al. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int. 2007;100(Suppl 1):1–5.
   PubMed Web of Science ®Google Scholar
• Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin. 2006;22:649–655.
   PubMed Web of Science ®Google Scholar
• Schwendeman SP, Shah RB, Bailey BA, et al. Injectable controlled release depots for large molecules. J Control Release. 2014;190:240–253.
   PubMed Web of Science ®Google Scholar
• Wright JC. Critical variables associated with nonbiodegradable osmotically controlled implants. AAPS J. 2010;12(3):437–442.
   PubMed Web of Science ®Google Scholar
• Fowler JE Jr, Gottesman JE, Reid CF, et al. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol. 2000;164:730–734.
   PubMed Web of Science ®Google Scholar
• Fowler JE, Flanagan M, Gleason DM, et al. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology. 2000;55:639–642.
   PubMed Web of Science ®Google Scholar
• Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (adt) predicts for time to castration- resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151–1156.
   PubMed Web of Science ®Google Scholar
• Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002;168:1199–1203.
   PubMed Web of Science ®Google Scholar
• Perez-Marreno R, Chu FM, Gleason D, et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002;24:1902–1914.
   PubMed Web of Science ®Google Scholar
• Braeckman J, Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci. 2014;10:477–483.
   PubMed Web of Science ®Google Scholar
• Mostafa NM, Chwalisz K, Larsen L, et al. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer. Clin Pharmacol Drug Dev. 2014;3:270–275.
   PubMed Web of Science ®Google Scholar
• Sartor O, Dineen MK, Perez-Marreno R, et al. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. 2003;62:319–323.
   PubMed Web of Science ®Google Scholar
• Spitz A, Young JM, Larsen L, et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:93–99.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175:533–536.
   PubMed Web of Science ®Google Scholar
• Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology. 2011;11:15.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Moul JW, Sartor O, et al. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015;11:1465–1474.
   PubMed Web of Science ®Google Scholar
• Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv. 2012;9:343–354.
   PubMed Web of Science ®Google Scholar
• Moul JW. Utility of LHRH antagonists for advanced prostate cancer. Can J Urol. 2014;21(Supp 1):22–27.
   PubMed Web of Science ®Google Scholar
• Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol. 2012;14:1–12.
   PubMedGoogle Scholar
• Barkin J, Burton S, Lambert C. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix. Can J Urol. 2016;23:8179–8183.
   PubMed Web of Science ®Google Scholar
• Karunasinghe N, Zhu Y, Han DY, et al. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism? BMC Urol. 2016;16:48.
   PubMed Web of Science ®Google Scholar
• Van Asseldonk B, Black P, Elterman DS. Chemical vs surgical ADT in metastatic prostate cancer: a comparison of side effects. Commentary on comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen deprivation therapy. Urology. 2016;93:3–4.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–836.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164.
   PubMed Web of Science ®Google Scholar
• Sidaway P. Prostate cancer: treatment with ADT impairs cognitive performance. Nat Rev Urol. 2015;12:361.
   PubMedGoogle Scholar
• Lee M, Jim HS, Fishman M, et al. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology. 2015;24:472–477.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Namiki M, Fujimoto T, et al. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol. 2015;45:1168–1174.
   PubMed Web of Science ®Google Scholar
• Cheung AS, Hoermann R, Dupuis P, et al. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol. 2016;175:229–237.
   PubMed Web of Science ®Google Scholar
• Perner S, Cronauer MV, Schrader AJ, et al. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 2015;6:35542–35555.
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Hammerer P, Rozet F, et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015;33:1079–1085.
   PubMed Web of Science ®Google Scholar
• Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;20(32):3705–3715.
   Web of Science ®Google Scholar
• Schweizer MT, Huang P, Kattan MW, et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer. 2013;119:3610–3618.
   PubMed Web of Science ®Google Scholar